Aura Biosciences (AURA) Cash from Investing Activities (2020 - 2026)

Aura Biosciences (AURA) has 7 years of Cash from Investing Activities data on file, last reported at $54.9 million in Q1 2026.

• Quarterly Cash from Investing Activities rose 84.14% year-over-year to $54.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $60.7 million (down 32.0% YoY) and the FY2025 annual result came in at $35.6 million, down 48.28% from the prior year.
• Cash from Investing Activities improved to $54.9 million in Q1 2026, from $29.8 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $54.9 million in Q1 2026 to a low of -$90.1 million in Q4 2023.
• A 5-year average of -$1.3 million and a median of $17.9 million in 2022 frame the typical range for Cash from Investing Activities.
• The widest YoY moves for Cash from Investing Activities: up 3231.94% in 2022, down 35812.68% in 2022.
• Tracing AURA's Cash from Investing Activities over 5 years: stood at -$16.9 million in 2022, then tumbled by 434.01% to -$90.1 million in 2023, then soared by 132.95% to $29.7 million in 2024, then climbed by 0.43% to $29.8 million in 2025, then soared by 84.07% to $54.9 million in 2026.
• The last three Cash from Investing Activities figures came in at $54.9 million (Q1 2026), $29.8 million (Q4 2025), and -$44.0 million (Q3 2025), per Business Quant data.